Thus, neutralizing antibodies, ACE2-derived peptides, and small molecules that could bind to the spike protein or ACE2 have been investigated as promising therapeutic approaches for the treatment of COVID-19 [37, 38], as these molecules disrupt the interaction between the spike protein and ACE2, which is the first step in viral infection. This evidence concerns the gene ACE2 and COVID-19.